Top

Faye M. Johnson, M.D., Ph.D.

Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine

About Dr. Faye M. Johnson

The research in my laboratory is directed at defining the biological and molecular effects of the modulation of signal transduction pathways in lung, head and neck, and HPV+ cancers. We have defined novel mechanisms of sensitivity and resistance to kinase inhibitors. The three main projects are:

We recently discovered that head and neck squamous cell carcinoma (HNSCC) tumors harboring NOTCH1 mutations were more sensitive to drugs targeting the PI3K/mTOR pathway than HNSCC cell lines with wild-type NOTCH1 receptors. Goals of this project are to: Determine the efficacy of PI3K/mTOR pathway inhibition in HNSCC patients with tumors that harbor inactivating NOTCH1 mutations; Elucidate the molecular mechanism underlying PI3K/mTOR dependency and sensitivity to drugs targeting this pathway in NOTCH1 mutant HNSCC; and Identify therapeutic targets that work in combination with PI3K/mTOR inhibitors to prevent resistance and maximize killing of NOTCH1 mutant HNSCC.

We published the first large-scale, integrated analysis to determine mechanisms of polo-like kinase 1 (PLK1) inhibitor-induced apoptosis in NSCLC by assessing gene/protein expression, gene mutation, and PLK1 inhibitor sensitivity. Mesenchymal NSCLC cell lines were more sensitive to PLK1 inhibitors than epithelial NSCLC. Indeed, inducing an epithelial phenotype increased resistance and inducing a mesenchymal phenotype increased sensitivity. We are investigating candidate pathways that underlie sensitivity to PLK inhibition.

A recently completed screen of 1122 compounds in HPV+ cancer cell lines identified clinically-relevant Aurora kinase inhibitors as effective drugs. Integrated analysis of genomics, proteomics, gene expression, and drug sensitivity has identified several candidate pathways of resistance that are currently being studied.

Primary Appointment

Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Research Interests

Education & Training

Degree-Granting Education

1996	University of Texas Graduate School of Biomedical Sciences MD Anderson Cancer Center, Houston, Texas, US, Cancer Biology, Ph.D
1996	University of Texas Medical School at Houston, Houston, Texas, US, MD
1989	The Johns Hopkins University, Baltimore, Maryland, US, Biology, BA

Postgraduate Training

2002-2003	Chief Medical Oncology Fellow, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
2000-2002	Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
1997-2000	Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, Texas

Licenses & Certifications

2022	Georgia Medical License
2022	Alabama Medical License
2022	Arizona Medical License
2022	Louisiana Medical License
2022	Washington Medical License
2022	Tennesee Medical License
2022	Oklahoma Medical License
2022	Mississippi Medical License
2003	Medical Oncology
2000	Internal Medicine
1998	Texas Medical License

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2021

Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003 - 2010

Administrative Appointments/Responsibilities

Committee Chair, Thoracic/Head and Neck Medical Oncology ACP Working Group, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer, Houston, TX, 2020 - 2023

Chief, Section of Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2018

Co-Director, Head and Neck CCSG, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2017

Other Professional Positions

Member, MD Anderson Head and Neck SPORE Internal Advisory Board on HPV-negative Squamous Cell Carcinomas, Houston, TX, 2024 - Present

Co-Chair, Steering Committee for the 2024 Multidisciplinary Head and Neck Cancers Symposium, Phoenix, AZ, 2024 - Present

Member, External Advisory Board, University of Chicago Head and Neck Cancer Specialized Program of Research Excellence (SPORE), Chicago, IL, 2022 - 2023

Chair, Steering Committee for the 2024 Multidisciplinary Head and Neck Cancers Symposium, Phoenix, AZ, 2022 - 2024

Chair-Elect, Steering Committee for the 2022 Multidisciplinary Head and Neck Cancers Symposium, Phoenix, AZ, 2020 - 2022

Annual Meeting Educational Program, Member, ASCO, Alexandria, VA, 2018 - 2019

Chair, ASCO, Annual Meeting Scientific Program Committee - Head & Neck Cancer, Alexandria, VA, 2018 - 2019

Annual Meeting Scientific Program Committee - Head & Neck Cancer, American Society of Clinical Oncology (ASCO), Member, Alexandria, VA, 2017 - 2020

Leader, Discovery Program, HPV Moonshot, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2018

Leader, Target & Drug Discovery Program, Lung Cancer Moon Shot, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2015

Director, The University of Texas MD Anderson Cancer Center -THNMO Laboratory Program, Houston, TX, 2012 - 2015

Chair, The University of Texas MD Anderson Cancer Center - Reuben Lotan Lecture, Houston, TX, 2012 - Present

Extramural Institutional Committee Activities

Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2024 - 2025

Member, InPACT Study -Correlative Sciences Committee, The University of Texas MD Anderson Cancer Center, 2023 - 2025

Teacher, Serious Illness Conversation Guide, The University of Texas MD Anderson Cancer Center, 2022 - 2023

Member, Mid-tenure review committee for Dr. Georgios Karras, The University of Texas MD Anderson Cancer Center, 2022

Member, Senate Research Affairs Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2024

Member, Mid-Career Faculty Group, The University of Texas MD Anderson Cancer Center, 2020 - 2021

Member, Research Integrity Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2021

Member, MD/PhD Program (MSTP) Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present

Member, Faculty Senate Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2022

Member, Mike Hogg Award & Lecture Subcommittee, The University of Texas MD Anderson Cancer Center, 2017 - Present

Reviewer, Division of Cancer Medicine’s 11th Annual Faculty Recognition & Awards Program, The University of Texas MD Anderson Cancer Center, 2017

Member, Institutional Staging Workgroup, The University of Texas MD Anderson Cancer Center, 2017 - 2018

Reviewer, Faculty Recognition and Awards Program, The University of Texas MD Anderson Cancer Center, 2016 - 2017

Member, Survey Governance Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2015

Member, Physician Scientist Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present

Member, Medical Quality Planning Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2016

Member, Ambulatory Order Sets (eCSR) Enhancement Advisory Workgroup, The University of Texas MD Anderson Cancer Center, 2014 - 2015

Chair, Medical Practice Committee, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2013 - 2015

Chair, Faculty Appeals Committee, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2012 - 2012

Vice Chair, Medical Practice Committee, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2011 - 2013

Member, Faculty Senate Committee, MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2010 - 2012

Member, Medical Practice Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2011

Reviewer, Division of Cancer Medicine Faculty Awards, The University of Texas MD Anderson Cancer Center

Retreat Judge, TAP Retreat Planning Committee, The University of Texas MD Anderson Cancer Center

Reviewer, Division of Cancer Medicine's 3rd Annual Research Awards, The University of Texas MD Anderson Cancer Center

Editorial Activities

Editor/Service on Editorial Board(s), Clinical Cancer Research, 2013 - Present

Editor/Service on Editorial Board(s), American Journal of Translational Research, 2011 - 2016

Editor/Service on Editorial Board(s), Anti-Cancer Drugs, 2006 - 2013

Honors & Awards

2017	Robert M. Chamberlain Distinguished Mentor Award - Nominee, UT MD Anderson Cancer Center
2013	LCRF Scientific Merit Award, Lung Cancer Research Foundation
2010 - 2011	Nominee in Recognition of Mentoring Excellence, MD Anderson Post-Doctoral Association
2003	Leventhal Scholar Award, Women in Cancer Research
2001	ASCO/AACR fellowship for the workshop Methods in Clinical Cancer Research

Professional Memberships

Society for Immunotherapy of Cancer (SITC)

2022 - Present

National Education Association

2022 - Present

American Head and Neck Society (AHNS)

2021 - Present

Alpha Omega Alpha Honor Medical Society

2019 - Present

European Society for Medical Oncology (ESMO)

2018 - Present

American Association for the Advancement of Science

2016 - Present

International Association for The Study of Lung Cancer

2003 - 2018

American Medical Association

2003 - Present

American Society of Clinical Oncology

2002 - Present

Texas Faculty Association

2002 - Present

Harris County Medical Association

2002 - Present

American Association for Cancer Research

1995 - Present

Selected Presentations & Talks

Local Presentations

2024. Medical Scientist Training Program. Invited. Houston, Texas, US.
2020. Cullen Trust for Higher Education MD/PhD Symposium. Conference. UT Health McGovern Medical School. Houston, TX, US.
2015. Mechanisms of Apoptosis Following Polo-like Kinase Inhibition in Head and Neck Squamous Cell Carcinoma. Conference. MD Anderson Cancer Center. Houston, TX, US.
2010. A novel feedback pathway leading to STAT3 activation following c-SRC inhibition. Conference. MD Anderson Cancer Center. Houston, TX, US.

National Presentations

2024. The combination of TRIP13 and Aurora kinase A inhibition results in cell cycle specific DNA damage and death in HPV-driven cancers. Invited. Center for Craniofacial Molecular Biology (CCMB) of the University of Southern California (USC), CA, US.
2021. Head and Neck Cancers: Poised for a Precision Medicine Revolution. Invited. Winship Cancer Institute of Emory University, US.
2019. Oncology Grand Rounds. Invited. Houston Methodist Cancer Center. Houston, TX, US.
2019. Head and Neck Cancer Takeaways. Invited. American Society of Clinical Oncology. Chicago, IL, US.
2018. Redefining Perceptions in Locally Advanced Disease. Invited. American Society of Clinical Oncology Annual Meeting, Chicago, IL. Chicago, IL, US.
2018. 10th Annual Cullen MD/PhD Colloquium & Workshop. Invited. UT Health - Graduate School of Biomedical Sciences. Houston, TX, US.
2018. Head and Neck Cancer Takeaways. Invited. American Society of Clinical Oncology. Chicago, IL, US.
2017. Puerto Rico Cancer Conferences Series 2017: Head and Neck Cancer Management. Invited. Ponce School of Medicine & Health Sciences, PR.
2017. Advanced Topics in Cancer: Emerging Technologies for Detection and Treatment of Cancer. Invited. University of Puerto Rico Comprehensive Cancer Center. San Juan, PR.
2015. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Invited. Texas A&M University. Houston, TX, US.
2015. Recent Advances in the Development of Combinatorial Therapies for Cancer. Invited. Institute of Biosciences and Technology - Texas A&M Health Science Center, US.
2014. Drug Sensitivity and Resistance: Improving Cancer Therapy. Invited. AACR Precision Medicine Series. Orlando, FL, US.
2014. Advances in the Understanding of Lung Cancer Biology: Translation to Clinical Practice. Visiting. University of Puerto Rico, PR.
2013. Advances in Lung Cancer Biology. Invited. Puerto Rico Association of Hematology and Medical Oncology. San Juan, PR.
2013. Novel Signaling Pathways as Therapeutic Targets in Lung and Head and Neck Cancer. Invited. University of Miami. Miami, FL, US.
2013. Discussion Panel, Manejo Multidiciplinario del Paciente Oncological. Conference. Discussion Panel, Manejo Multidiciplinario del Paciente Oncological. Houston, TX, US.
2013. BEZ235 Targeted Therapy for Lung Cancer. Invited. International Association for the Study of Lung Cancer. San Monica, CA, US.
2012. Dasatinib, Targeted Therapies for the Treatment of lung cancer, International Association for the Study of Lung Cancer. Invited. International Association for the Study of Lung Cancer. San Monica, CA, US.
2012. Grand Rounds. Invited. University of Pittsburgh Medical Center. Pittsburgh, PA, US.
2012. Small Cell Lung Cancer. Invited. Baylor College of Medicine. Houston, TX, US.
2011. Targeted Therapy for Lung Cancer. Invited. Chinese Society for Clinical Oncology Targeted Therapy Conference, CN.
2010. Small Cell Lung Cancer. Invited. Baylor College of Medicine, Hematology and Oncology. Houston, TX, US.
2010. JAK Activation as a Mechanism for Resistance to c-Src Inhibition in NSCLC. Invited. Molecular Origins of Lung Cancer. Coronado, CA, US.
2009. The Role of JAK Activation Following Sustained c-Src Inhibition. Invited. The University of Michigan Cancer Center Seminar. Ann Arbor, MI, US.
2009. Sustained c-Src Inhibition Results in JAK/STAT3 Activation Allowing Cancer Cell Survival in Lung and Head and Neck Cancers. Invited. University of Colorado Cancer Center. Denver, CO, US.
2009. The Src Inhibitor KX2-391 Targeted Therapies for the Treatment of lung Cancer. Invited. International Association for the Study of Lung Cancer. San Monica, CA, US.
2008. Src Family Kinases as Therapeutic Targets in Cancer. Invited. Moffitt Cancer Center, Ground Rounds. Tampa, FL, US.
2008. Molecular and Biological Effects of Src Family Kinase Inhibition in Head and Neck Cancer. Invited. American Association for Cancer Research. San Diego, CA, US.
2008. Src Family Kinases as Therapeutic Targets in Lung Cancer. Targeted Therapies for the Treatment of Lung Cancer. Invited. International Association for the Study of Lung Cancer. Santa Monica, CA, US.
2003. The tyrosine kinase inhibitor ST1571 induces COX-2 expression and PGE2 accumulation in head and neck squamous cell carcinoma via activation of MAPK. Invited. American Association for Cancer Research. Washington, DC, US.

International Presentations

2025. Advanced Topics in Cancer Research: Cancer Disparities in Puerto Rico. Invited. UPR/MDACC Partnership U54, PR.
2023. Advanced Topics in Cancer Research: Cancer Disparities in Puerto Rico. Invited. UPR/MDACC Partnership U54, US.
2017. "Frontiers in Cancer Research and Therapy" - Targeting polo-like kinase 1 in mesenchymal non-small cell lung cancer. Invited. Karolinska Institutet. Stockholm, SE.
2016. Prevention and Treatment of Cancer:Hypes and Hopes. Invited. Gujarat Cancer & Research Institute Gujarat Cancer Society. Ahmedabad, IN.
2013. Novel Signaling Pathways as Therapeutic Targets in Lung and Head & Neck Cancers. Invited. Zhejiang Cancer Hospital. Hangzhou, CN.
2011. Advances in Lung Cancer Biology. Invited. Puerto Rico Association of Hematology and Medical Oncology. San Juan, PR.

Less

Grant & Contract Support

Date:	2025 - 2028
Title:	Synthetic lethality of TRIP13 and Aurora A in Rb-deficient cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	RP250398

Date:	2024 - 2029
Title:	OPC SURVIVOR: Optimizing OroPharyngeal Cancer SURVivorship
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	5P01CA285249-02

Date:	2023 - 2024
Title:	Synthetic lethality of Aurora kinase A and TRIP13 in Rb-deficient cancers
Funding Source:	UT Austin/MD Anderson Cancer Center Collaborative Pilot Project Grant
Role:	Co-PI

Date:	2022 - 2027
Title:	Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	1 R01 CA269516-01

Date:	2022 - 2024
Title:	Development of TRIP13 Inhibitors for Treatment of HPV+ Cancers
Funding Source:	NIH/NCI
Role:	PI
ID:	U54CA96300

Date:	2022 - 2027
Title:	Leveraging Hyperpolarized MRI for Precision Oncology Approaches in Head and Neck Cancer
Funding Source:	NIH/NIDCR
Role:	Significant Contributor
ID:	1R01CA280980-01A1

Date:	2021 - 2022
Title:	Nanatinostat in Human Papillomavirus (HPV)+ Squamous Cancers
Funding Source:	Viracta Therapeutics
Role:	PI

Date:	2021 - 2022
Title:	Selective depletion of myeloid-derived suppressor cells in HPV+ cancers
Funding Source:	MDACC/IRG
Role:	PI

Date:	2020 - 2021
Title:	Topoisomerase II inhibition-induced pyroptosis in human papillomavirus-driven head and neck squamous carcinoma
Funding Source:	The University of Texas MD Anderson Cancer Center-Oropharynx Cancer Program
Role:	PI

Date:	2020 - 2025
Title:	Harnessing Aurora kinase inhibition‐induced cell death to enhance immunotherapy in HPV‐driven cancers
Funding Source:	NIH/NCI
Role:	PI
ID:	R01 CA248205-02

Date:	2020 - 2023
Title:	Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC)
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Principal Investigator-MDACC
ID:	RP200369

Date:	2019 - 2020
Title:	MD Anderson Oropharynx Cancer Program - Discovery Section: Aurora Kinase Inhibition in Oropharynx Cancer
Funding Source:	University of Texas MD Anderson
Role:	PI

Date:	2019 - 2021
Title:	Aurora kinase A inhibition-induced cell death to enhance immunotherapy in HPV-driven cancer
Funding Source:	Takeda
Role:	PI
ID:	57438

Date:	2019 - 2024
Title:	Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC)
Funding Source:	NIH/NCI
Role:	PI
ID:	1R01CA235620-04

Date:	2019 - 2020
Title:	MD Anderson Oropharynx Program: Stiefel Database
Funding Source:	University of Texas MD Anderson
Role:	PI

Date:	2017 - 2019
Title:	LC 160206 Novel therapy strategies for mesenchymal non-small cell lung cancer
Funding Source:	Department of Defense (DOD)
Role:	PI
ID:	RFA W81XWH-16-LCRP-IITRA

Date:	2017 - 2019
Title:	Extension of Radiotherapy Research
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01 CA168485 (JIT)

Date:	2016 - 2019
Title:	Mechanisms and Consequences of NOTCH Dysfunction in Head and Neck Cancer
Funding Source:	NIH/NIDCR
Role:	Co-I
ID:	5 R01 DE024179-03

Date:	2015 - 2019
Title:	Translating Genomic Alterations into Novel Therapeutic Targets in Head and Neck Cancer through Computational and Functional Approaches
Funding Source:	NIH/NIDCR
Role:	Co-I
ID:	1 U01 DE 025181-01

Date:	2014 - 2019
Title:	Stiefel Discovery Grant
Funding Source:	Stiefel Discovery
Role:	Co-I

Date:	2014 - 2018
Title:	HPV Moonshot Flagship
Funding Source:	UT MD Anderson Cancer Center
Role:	Co-I

Date:	2014 - 2017
Title:	PIQUR Therapeutics AG
Funding Source:	PIQUR Therapeutics AG
Role:	PI

Date:	2014 - 2019
Title:	Predicting and overcoming chemoradioresistance in p53-mutant head and neck cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R01 DE024601-01

Date:	2014 - 2021
Title:	Lerryn M Carl Lung Cancer Research
Funding Source:	Lerryn M Carl Lung Cancer Research
Role:	PI

Date:	2013 - 2016
Title:	Mechanisms that regulate therapeutic response to polo-like kinase inhibitors in non-small cell lung cancer
Funding Source:	Lung Cancer Research Foundation
Role:	PI

Date:	2013 - 2015
Title:	Lung Cancer Moon Shot
Funding Source:	Lung Cancer Research Fund
Role:	Co-I

Date:	2013 - 2017
Title:	Cancer Center Support (CCSG) Grant – Head and Neck Program 5
Funding Source:	NIH/NCI
Role:	Co-Program Leader
ID:	5 P30 CA016672 38

Date:	2012 - 2014
Title:	BRAF-mediated senescence in lung cancer
Funding Source:	American Lung Association
Role:	PI

Date:	2010 - 2015
Title:	Targeting c-Src in Head and Neck Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	R01CA143369-02

Date:	2009 - 2010
Title:	The Receptor Tyrosine Kinase EphA2: A Potential Therapeutic Target for EGFR-Dependent Lung Cancers
Funding Source:	Joan Scarangello Foundation
Role:	PI

Date:	2008 - 2011
Title:	SPORE in Lung Cancer
Funding Source:	NIH
Role:	Investigator
ID:	5 P50 CA70907

Date:	2007 - 2008
Title:	Developmental Research Project
Funding Source:	The University of Texas SPORE in Head and Neck Cancer
Role:	PI
ID:	P50CA97007

Date:	2006 - 2007
Title:	Career Development Award
Funding Source:	The University of Texas SPORE in Lung Cancer
Role:	PI
ID:	P50CA70907

Date:	2006 - 2011
Title:	Early Therapeutics Development with Phase II Emphasis
Funding Source:	NIH/NCI
Role:	Co-I
ID:	N01-CM-62202

Date:	2003 - 2008
Title:	Physician Scientist Award Grant
Funding Source:	MD Anderson Cancer Center
Role:	Investigator

Date:	2002 - 2013
Title:	Head & Neck SPORE
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5 P50 CA097007-10

Selected Publications

Peer-Reviewed Articles

Moreno AC, Sahli A, Johnson FM, Sun X, Barbon C, Rinsurongkawong W, Song W, Luciani F, Liang H, Li J, Liu W, Lee J, Frank SJ, Lai SY, Fuller CD, Hutcheson K. Stiefel MD Anderson OroPharynx Cancer (MDA-OPC) Cohort – A Single Institution, Prospective Longitudinal Outcomes Study. BMJ, 2025. e-Pub 2025. PMID: 41290309.
Yadollahi P, McCord KA, Li Y, Dayoub H, Saab K, Essien F, Hyslop S, Kan E, Ahmed KM, Kirby PR, Putluri V, Ambati CSR, Kami Reddy KR, Castro P, Skinner HD, Coarfa C, Decker WK, Osman AA, Patel R, Myers JN, Lai SY, Putluri N, Johnson FM, Frederick MJ, Hudson WH, Sandulache VC. Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting. Br J Cancer, 2025. e-Pub 2025. PMID: 41053162.
Shah PA, Mazumdar T, Ghosh S, Yapindi L, Powell RT, Park YS, Shen L, Fernandez AM, Stephan CC, Wang J, Sikora AG, Kazi J, Frederick MJ, Johnson FM. Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma. Cancer Lett 625:217814, 2025. e-Pub 2025. PMID: 40412794.
Sammons RM, Ghosh S, Yapindi L, Cho EJ, Johnson FM, Dalby KN. Advancing the development of TRIP13 inhibitors: A high-throughput screening approach. SLAS Discov 33:100233, 2025. e-Pub 2025. PMID: 40228580.
Yadollahi P, McCord KA, Li Y, Dayoub H, Saab K, Essien F, Hyslop S, Kan E, Ahmed KM, Kirby PR, Putluri V, Ambati CSR, Kami Reddy KR, Castro P, Skinner HD, Coarfa C, Decker WK, Osman AA, Patel R, Myers JN, Lai SY, Putluri N, Johnson FM, Frederick MJ, Hudson WH, Sandulache VC. Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting. bioRxiv, 2025. e-Pub 2025. PMID: 39868226.
Ghosh S, O'Hara MP, Sinha P, Mazumdar T, Yapindi L, Sastry JK, Johnson FM. Targeted inhibition of Aurora kinase A promotes immune checkpoint inhibition efficacy in human papillomavirus-driven cancers. J Immunother Cancer 13(1), 2025. e-Pub 2025. PMID: 39773561.
Johnson FM, O'Hara MP, Yapindi L, Jiang P, Tran HT, Reuben A, Xiao W, Gillison M, Sun X, Khalaf A, Lee JJ, Sastry JK, Ghosh S. Phase 1/2 Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas. Clin Cancer Res, 2024. e-Pub 2024. PMID: 39589337.
Carlander AF, Bendtsen SK, Rasmussen JH, Jakobsen KK, Garset-Zamani M, Grønhøj C, Friborg J, Hutcheson K, Johnson FM, Fuller CD, Moreno AC, Babarinde T, Gross ND, Myers JN, von Buchwald C. Clinical and prognostic differences in oropharyngeal squamous cell carcinoma in USA and Denmark, two HPV high-prevalence areas. Eur J Cancer 202:113983, 2024. e-Pub 2024. PMID: 38452723.
Anderson BJ, Moreno AC, Qing Y, Lee JJ, Johnson FM, Lango MN, Barbon CEA, Tripuraneni L, Sahli A, Piper V, Gross N, Fuller CD, Lai SY, Myers JN, Hutcheson KA. Revisiting Feeding Tube Utilization in Oropharynx Cancer: 6-Year Prospective Registry Analysis. Otolaryngol Head Neck Surg 170(5):1319-1330, 2024. e-Pub 2024. PMID: 38353360.
Yu W, Chen Y, Putluri N, Osman A, Coarfa C, Putluri V, Kamal AHM, Asmussen JK, Katsonis P, Myers JN, Lai SY, Lu W, Stephan CC, Powell RT, Johnson FM, Skinner HD, Kazi J, Ahmed KM, Hu L, Threet A, Meyer MD, Bankson JA, Wang T, Davis J, Parker KR, Harris MA, Baek ML, Echeverria GV, Qi X, Wang J, Frederick AI, Walsh AJ, Lichtarge O, Frederick MJ, Sandulache VC. Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state. Br J Cancer 128(11):2013-2024, 2023. e-Pub 2023. PMID: 37012319.
Johnson FM, Janku F, Gouda MA, Tran HT, Kawedia JD, Schmitz D, Streefkerk H, Lee JJ, Andersen CR, Deng D, Rawal S, Shah PA, El-Naggar AK, Johnson JM, Frederick MJ. Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer. Oncologist 27(12):1004-e926, 2022. e-Pub 2022. PMID: 36124629.
Shah PA, Sambandam V, Fernandez AM, Zhao H, Mazumdar T, Shen L, Wang Q, Ahmed KM, Ghosh S, Frederick MJ, Wang J, Johnson FM. Sustained Aurora kinase B expression confers resistance to PI3K inhibition in head and neck squamous carcinoma. Cancer Res 82(23):4444-4456, 2022. e-Pub 2022. PMID: 36169922.
Ghosh S, Mazumdar T, Xu W, Powell RT, Stephan C, Shen L, Shah PA, Pickering CR, Myers JN, Wang J, Frederick MJ, Johnson FM. Combined TRIP13 and Aurora kinase inhibition induces apoptosis in human papillomavirus-driven cancers. Clin Cancer Res 28(20):4479-4493, 2022. e-Pub 2022. PMID: 35972731.
Barbon CEA, Peterson CB, Moreno AC, Lai SY, Reddy JP, Sahli A, Martino R, Johnson FM, Fuller CD, Hutcheson KA. Adhering to Eat and Exercise Status During Radiotherapy for Oropharyngeal Cancer for Prevention and Mitigation of Radiotherapy-Associated Dysphagia. JAMA Otolaryngol Head Neck Surg 148(10):956-964, 2022. e-Pub 2022. PMID: 36074459.
Barbon CEA, Yao CMK, Peterson CB, Moreno AC, Goepfert RP, Johnson FM, Chronowski GM, Fuller CD, Gross ND, Hutcheson KA. Swallowing After Primary TORS and Unilateral or Bilateral Radiation for Low- to Intermediate-Risk Tonsil Cancer. Otolaryngol Head Neck Surg 167(3):1945998211059967, 2022. e-Pub 2022. PMID: 34784256.
Pantaleón García J, Kulkarni VV, Reese TC, Wali S, Wase SJ, Zhang J, Singh R, Caetano MS, Kadara H, Moghaddam SJ, Johnson FM, Wang J, Wang Y, Evans SE. OBIF: an omics-based interaction framework to reveal molecular drivers of synergy. NAR Genom Bioinform 4(2):lqac028, 2022. e-Pub 2022. PMID: 35387383.
Le X, Gleber-Netto FO, Rubin ML, Qing Y, Du R, Kies M, Blumenschein G, Lu C, Johnson FM, Bell D, Lewis J, Zhang J, Feng L, Wilson K, Marcelo-Lewis K, Wang J, Ginsberg L, Gillison M, Lee JJ, Meric-Bernstam F, Mills GB, William WN, Myers JN, Pickering CR. Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clin Cancer Res. e-Pub 2022. PMID: 35443062.
Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res 28(8):1735, 2022. e-Pub 2022. PMID: 35419587.
Sousa LG, Rajapakshe K, Rodriguez Canales J, Chin RL, Feng L, Wang Q, Barrese TZ, Massarelli E, William W, Johnson FM, Ferrarotto R, Wistuba I, Coarfa C, Lee J, Wang J, Melief CJM, Curran MA, Glisson BS. ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response. J Immunother Cancer 10(2), 2022. e-Pub 2022. PMID: 35193933.
Callahan SC, Kochat V, Liu Z, Raman AT, Divenko M, Schulz J, Terranova CJ, Ghosh AK, Tang M, Johnson FM, Wang J, Skinner HD, Pickering CR, Myers JN, Rai K. High Enhancer Activity is an Epigenetic Feature of HPV Negative Atypical Head and Neck Squamous Cell Carcinoma. Front Cell Dev Biol 10:936168, 2022. e-Pub 2022. PMID: 35927986.
Kumar M, Molkentine D, Molkentine J, Bridges K, Xie T, Yang L, Hefner A, Gao M, Bahri R, Dhawan A, Frederick MJ, Seth S, Abdelhakiem M, Beadle BM, Johnson F, Wang J, Shen L, Heffernan T, Sheth A, Ferris RL, Myers JN, Pickering CR, Skinner HD. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nat Commun 12(1):6340, 2021. e-Pub 2021. PMID: 34732714.
Barbon CE, Peterson CB, Fuller CD, Lai S, Moreno AC, Johnson FM, Hutcheson KA. Prospective Validation of the Use It or Lose It Paradigm: Secondary Analysis of Sub-Acute Dietary Outcomes by Eat and Exercise Status During Oropharyngeal Radiotherapy. Int J Radiat Oncol Biol Phys:e408-e409, 2021. e-Pub 2021. PMID: 34701381.
Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, Fan Y, Kundu K, Gao B, Avila K, Pickering CR, Johnson FM, Zhang J, Kadara H, Minna JD, Gibbons DL, Wang J, Heymach JV, Byers LA. Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology. J Thorac Oncol 16(11):1821-1839, 2021. e-Pub 2021. PMID: 34274504.
Gudikote JP, Cascone T, Poteete A, Sitthideatphaiboon P, Wu Q, Morikawa N, Zhang F, Peng S, Tong P, Li L, Shen L, Nilsson M, Jones P, Sulman EP, Wang J, Bourdon JC, Johnson FM, Heymach JV. Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers. J Biol Chem 297(5):101163, 2021. e-Pub 2021. PMID: 34481841.
Maniakas A, Henderson YC, Hei H, Peng S, Chen Y, Jiang Y, Ji S, Cardenas M, Chiu Y, Bell D, Williams MD, Hofmann MC, Scherer SE, Wheeler DA, Busaidy NL, Dadu R, Wang JR, Cabanillas ME, Zafereo M, Johnson FM, Lai SY. Novel anaplastic thyroid cancer PDXs and cell lines: Expanding preclinical models of genetic diversity. J Clin Endocrinol Metab 106(11):e4652-e4665, 2021. e-Pub 2021. PMID: 34147031.
Henderson YC, Mohamed ASR, Maniakas A, Chen Y, Powell RT, Peng S, Cardenas M, Williams MD, Bell D, Zafereo ME, Wang RJ, Scherer SE, Wheeler DA, Cabanillas ME, Hofmann MC, Johnson FM, Stephan CC, Sandulache V, Lai SY. A High-Throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma. J Clin Endocrinol Metab 106(10):2962-2978, 2021. e-Pub 2021. PMID: 34120183.
Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Pilot phase II trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res 27(16):4557-4565, 2021. e-Pub 2021. PMID: 34187851.
Guo TW, Saiyed F, CMKL Y, Kiong KL, Martinez J, Sacks R, Lee JJ, Moreno AC, Frank SJ, Rosenthal DI, Glisson BS, Ferrarotto R, Mott FE, Johnson FM, Myers JN. Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. Cancer 127(16):2916-2925, 2021. e-Pub 2021. PMID: 33873251.
Saiyed FK, Guo T, Johnson F, Myers JN. Characterizing distant metastases and survival in oropharyngeal squamous cell carcinoma. Head Neck 43(7):2101-2109, 2021. e-Pub 2021. PMID: 33738875.
Mott FE, Bruera E, Johnson F. End-of-life and goals of care discussions with cancer patients in the coronavirus pandemic. Palliat Support Care 19(3):1-2, 2021. e-Pub 2021. PMID: 32814600.
Tam S, Gajera M, Luo X, Glisson BS, Ferrarotto R, Johnson FM, Mott FE, Gillison ML, Lu C, Le X, Blumenschein GR, Wong MK, Rosenthal DI, Nagarajan P, El-Naggar AK, Midgen MR, Weber RS, Myers JN, Gross ND. Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck 43(5):1592-1603, 2021. e-Pub 2021. PMID: 33522021.
Dahlstrom KR, Song J, Thall PF, Fuller CD, Hutcheson KA, Johnson FM, Gunn GB, Phan J, Frank SJ, Morrison WH, Ferrarotto R, Rosenthal DI, Sturgis EM, Garden AS. Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. Cancer 127(8):1228-1237, 2021. e-Pub 2021. PMID: 33306202.
Ng SP, Bahig H, Jethanandani A, Sturgis EM, Johnson FM, Elgohari B, Gunn GB, Ferrarotto R, Phan J, Rosenthal DI, Frank SJ, Fuller CD, Garden AS. Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy. Br J Cancer 124(3):628-633, 2021. e-Pub 2021. PMID: 33051590.
Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, Fan Y, Kundu K, Gao B, Avila K, Pickering CR, Johnson FM, Zhang J, Kadara H, Minna JD, Gibbons DL, Wang J, Heymach JV, Byers LA. SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models. bioRxiv, 2021. e-Pub 2021. PMID: 32577652.
Shah PA, Huang C, Li Q, Kazi SA, Byers LA, Wang J, Johnson FM, Frederick MJ. NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma. Cells 9(12), 2020. e-Pub 2020. PMID: 33322834.
Mott F, Sacks R, Johnson FM, Hutcheson KA, Gallagher N, Varghese S, Zaveri J. Subjective functional outcomes in oropharyngeal cancer treated with induction chemotherapy using the MD Anderson Symptom Inventory (MDASI). Laryngoscope Investigative Otolaryngology, 2020. e-Pub 2020.
Kamal M, Mohamed ASR, Fuller CD, Sturgis EM, Johnson FM, Morrison WH, Gunn GB, Hutcheson KA, Phan J, Volpe S, Ng SP, Phan J, Cardenas C, Ferrarotto R, Frank SJ, Rosenthal DI, Garden AS. Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. Adv Radiat Oncol 5(5):929-935, 2020. e-Pub 2020. PMID: 33083655.
Ferrarotto R, Bell D, Rubin ML, Hutcheson KA, Johnson JM, Goepfert RP, Phan J, Elamin YY, Torman DK, Warneke CL, Hessel AC, Garden AS, Myers JN, Johnson FM, Lee JJ, Sikora AG, Gillison ML, Glisson BS, Gross ND. Impact of neoadjuvant durvalumab with or without tremelimumab on CD8+ tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial. Clin Cancer Res 26(13):3211-3219, 2020. e-Pub 2020. PMID: 32269052.
Ng SP, Bahig H, Jethanandani A, Pollard C, Berends J, Sturgis EM, Johnson FM, Elgohari B, Elhalawani H, Rosenthal DI, Skinner HD, Gunn GB, Phan J, Frank SJ, Mohamed ASR, Fuller CD, Garden AS. Lymphopenia during radiotherapy in patients with oropharyngeal cancer. Radiother Oncol 145:95-100, 2020. e-Pub 2020. PMID: 31931292.
Hutcheson KA, Warneke CL, CMKL Y, Zaveri J, Elgohari BE, Goepfert R, Hessel AC, Kupferman ME, Lai SY, Fuller CD, Gunn GB, Garden AS, Johnson F, Ferrarotto R, Lewin JS, Gross ND, Head MD, Working Group NCS. Dysphagia After Primary Transoral Robotic Surgery With Neck Dissection vs Nonsurgical Therapy in Patients With Low- to Intermediate-Risk Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. e-Pub 2019. PMID: 31556933.
Sagiv O, Ding S, Ferrarotto R, Glisson B, Altan M, Johnson F, Elamin Y, Thakar SD, Nagarajan P, Esmaeli B. Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma. Ophthalmic Plast Reconstr Surg 35(4):350-353, 2019. e-Pub 2019. PMID: 30365473.
Sambandam V, Frederick MJ, Shen L, Tong P, Rao X, Peng S, Singh R, Mazumdar T, Huang C, Li Q, Pickering CR, Myers JN, Wang J, Johnson FM. PDK1 mediates NOTCH1-mutated head and neck squamous carcinoma vulnerability to therapeutic PI3K/mTOR inhibition. Clin Cancer Res 25(11):3329-3340, 2019. e-Pub 2019. PMID: 30770351.
Singh R, Peng S, Viswanath P, Sambandam V, Shen L, Rao X, Fang B, Wang J, Johnson FM. Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis. EMBO Mol Med 11(5), 2019. e-Pub 2019. PMID: 31040125.
Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, Garden AS, Blumenschein GR, William WN, Pharaon RR, Tishler RB, Glisson BS, Pickering C, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol 30(3):471-477, 2019. e-Pub 2019. PMID: 30596812.
Gleber-Netto FO, Rao X, Guo T, Xi Y, Gao M, Shen L, Erikson K, Kalu NN, Ren S, Xu G, Fisch KM, Akagi K, Seiwert T, Gillison M, Frederick MJ, Johnson FM, Wang J, Myers JN, Califano J, Skinner HD, Pickering CR. Variations in HPV function are associated with survival in squamous cell carcinoma. JCI Insight 4(1). e-Pub 2019. PMID: 30626753.
Gay CM, Tong P, Cardnell RJ, Sen T, Su X, Ma J, Bara RO, Johnson FM, Wakefield C, Heymach JV, Wang J, Byers LA. Differential Sensitivity Analysis for Resistant Malignancies (DISARM) identifies common candidate therapies across platinum-resistant cancers. Clin Cancer Res 25(1):346-357, 2019. e-Pub 2019. PMID: 30257981.
Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, Feng L, Lee JJ, Tran H, Kim YU, Haymaker C, Bernatchez C, Curran M, Zecchini Barrese T, Rodriguez Canales J, Wistuba I, Li L, Wang J, van der Burg SH, Melief CJ, Glisson B. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol 5(1):67-73, 2019. e-Pub 2019. PMID: 30267032.
Bloom BC, Augustyn A, Pezzi TA, Menon H, Mayo LL, Shah SJ, Schwartz DL, Chmura SJ, Johnson FM, Welsh JW, Chun SG. Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab. Front Oncol 9:223, 2019. e-Pub 2019. PMID: 31024834.
Viswanath P, Peng S, Singh R, Kingsley C, Balter PA, Johnson FM. A Novel Method for Quantifying Total Thoracic Tumor Burden in Mice. Neoplasia 20(10):975-984, 2018. e-Pub 2018. PMID: 30157470.
Kalu NN, Mazumdar T, Peng S, Tong P, Shen L, Wang J, Banerjee U, Myers JN, Pickering CR, Brunell D, Stephan CC, Johnson FM. Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants. Cancer Lett 431:64-72, 2018. e-Pub 2018. PMID: 29807113.
Rodon J, Pérez-Fidalgo A, Krop IE, Burris H, Guerrero-Zotano A, Britten CD, Becerra C, Schellens J, Richards DA, Schuler M, Abu-Khalaf M, Johnson FM, Ranson M, Edenfield J, Silva AP, Hackl W, Quadt C, Demanse D, Duval V, Baselga J. Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. Cancer Chemother Pharmacol 82(2):285-298, 2018. e-Pub 2018. PMID: 29882016.
Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Zinner R, Wheler J, Janku F, Fu S, Lim J, Bean S, Nguyen L, Urban S, Browne E, Meric-Bernstam F, Hong DS. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs 36(3):416-423, 2018. e-Pub 2018. PMID: 29047029.
Lee WC, Diao L, Wang J, Zhang J, Roarty EB, Varghese S, Chow CW, Fujimoto J, Behrens C, Cascone T, Peng W, Kalhor N, Moran CA, Weissferdt A, Johnson FM, William WN, Swisher SG, Lee JJ, Hong WK, Heymach JV, Wistuba II, Futreal PA, Zhang J. Multiregion gene-expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Mod Pathol 31(6):947-955, 2018. e-Pub 2018. PMID: 29410488.
Gold KA, Kies MS, William WN, Johnson FM, Lee JJ, Glisson BS. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. Cancer 124(10):2169-2173, 2018. e-Pub 2018. PMID: 29579331.
Kamal M, Mohamed ASR, Fuller CD, Sturgis EM, Johnson FM, Morrison WH, Gunn GB, Hutcheson KA, Phan J, Volpe S, Ng SP, Ferrarotto R, Frank SJ, Skinner HD, Rosenthal DI, Garden AS. Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity modulated radiation therapy. Cancer 124(7):1415-1427, 2018. e-Pub 2018. PMID: 29338089.
Gadhikar MA, Zhang J, Shen L, Rao X, Wang J, Zhao M, Kalu NN, Johnson FM, Byers LA, Heymach J, Hittelman WN, Udayakumar D, Pandita RK, Pandita TK, Pickering CR, Redwood AB, Piwnica-Worms H, Schlacher K, Frederick MJ, Myers JN. CDKN2A/p16 deletion in head and neck cancer cells is associated with Cdk2 activation, replication stress, and vulnerability to Chk1 inhibition. Cancer Res 78(3):781-797, 2018. e-Pub 2018. PMID: 29229598.
Tanaka N, Patel AA, Tang L, Silver NL, Lindemann A, Takahashi H, Jaksik R, Rao X, Kalu NN, Chen TC, Wang J, Frederick MJ, Johnson F, Gleber-Netto FO, Fu S, Kimmel M, Wang J, Hittelman WN, Pickering CR, Myers JN, Osman AA. Replication stress leading to apoptosis within the S-phase contributes to synergism between vorinostat and AZD1775 in HNSCC harboring high risk TP53 mutation. Clin Cancer Res 23(21):6541-6554, 2017. e-Pub 2017. PMID: 28790110.
Kalu NN, Mazumdar T, Peng S, Shen L, Sambandam V, Rao X, Xi Y, Li L, Qi Y, Gleber-Netto FO, Patel A, Wang J, Frederick MJ, Myers JN, Pickering CR, Johnson FM. Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines. Oncotarget 8(49):86369-86383, 2017. e-Pub 2017. PMID: 29156801.
Cardnell RJ, Li L, Sen T, Bara R, Tong P, Fujimoto J, Ireland AS, Guthrie MR, Bheddah S, Banerjee U, Kalu NN, Fan YH, Dylla SJ, Johnson FM, Wistuba II, Oliver TG, Heymach JV, Glisson BS, Wang J, Byers LA. Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget 8(43):73419-73432, 2017. e-Pub 2017. PMID: 29088717.
Quinlan-Davidson SR, Mohamed ASR, Myers JN, Gunn GB, Johnson FM, Skinner H, Beadle BM, Gillenwater AM, Phan J, Frank SJ, William WN, Wong AJ, Lai SY, Fuller CD, Morrison WH, Rosenthal DI, Garden AS. Outcomes of oral cavity cancer patients treated with surgery followed by postoperative intensity modulated radiation therapy. Oral Oncol 72:90-97, 2017. e-Pub 2017. PMID: 28797467.
Kawakami M, Mustachio LM, Rodriguez-Canales J, Mino B, Roszik J, Tong P, Wang J, Lee JJ, Myung JH, Heymach JV, Johnson FM, Hong S, Zheng L, Hu S, Villalobos PA, Behrens C, Wistuba I, Freemantle S, Liu X, Dmitrovsky E. Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. J Natl Cancer Inst 109(6), 2017. e-Pub 2017. PMID: 28376145.
Zhang M, Singh R, Peng S, Mazumdar T, Sambandam V, Shen L, Tong P, Li L, Kalu NN, Pickering CR, Frederick M, Myers JN, Wang J, Johnson FM. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Lett 392:71-82, 2017. e-Pub 2017. PMID: 28126323.
Quinlan-Davidson SR, Morrison WH, Myers JN, Gunn GB, William WN, Beadle BM, Skinner HD, Gillenwater AM, Frank SJ, Phan J, Johnson FM, Fuller CD, Zafereo ME, Rosenthal DI, Garden AS. Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. Head Neck 39(4):633-638, 2017. e-Pub 2017. PMID: 28006086.
Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, Kim S, Hirsch FR, Ellison K, Flaherty JT, Mills GB, Grandis JR. Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. JCI Insight 2(6):e90449, 2017. e-Pub 2017. PMID: 28352657.
Min HY, Lee SC, Woo JK, Jung HJ, Park KH, Jeong HM, Hyun SY, Cho J, Lee W, Park JE, Kwon SJ, Lee HJ, Ni X, Shin YK, Johnson FM, Duvic M, Lee HY. Essential role of DNA methyltransferase 1-mediated transcription of insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors. Clin Cancer Res 23(5):1299-1311, 2017. e-Pub 2017. PMID: 27582487.
Kalu NN, Johnson FM. Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?. Expert Opin Investig Drugs 26(2):207-217, 2017. e-Pub 2017. PMID: 28042706.
Garden AS, Fuller CD, Rosenthal DI, William WN, Gunn GB, Beadle BM, Johnson FM, Morrison WH, Phan J, Frank SJ, Kies MS, Sturgis EM. Reply to radiotherapy for human papillomavirus-positive oropharyngeal cancers in the National Cancer Data Base. Cancer 122(21):3411-3412, 2016. e-Pub 2016. PMID: 27420634.
Danilov AV, Hu S, Orr B, Godek K, Mustachio LM, Sekula D, Liu X, Kawakami M, Johnson FM, Compton DA, Freemantle SJ, Dmitrovsky E. Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin Dependent Kinases 1 and 2. Mol Cancer Ther 15(11):2758-2766, 2016. e-Pub 2016. PMID: 27550941.
Lee SC, Min HY, Jung HJ, Park KH, Hyun SY, Cho J, Woo JK, Kwon SJ, Lee HJ, Johnson FM, Lee HY. Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors. Oncogene 35(42):5515-5526, 2016. e-Pub 2016. PMID: 27086926.
Murone M, Vaslin Chessex A, Attinger A, Ramachandra R, Shetty SJ, Daginakatte G, Sengupta S, Marappan S, Dhodheri S, Rigotti S, Bachhav Y, Brienza S, Traxler P, Lang M, Aguet M, Zoete V, Michielin O, Nicholas C, Johnson FM, Ramachandra M, McAllister A. Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases. Mol Cancer Ther 15(10):2334-2343, 2016. e-Pub 2016. PMID: 27439479.
Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Oncotarget 7(30):47998-48010, 2016. e-Pub 2016. PMID: 27384992.
Garden AS, Fuller CD, Rosenthal DI, William WN, Gunn GB, Beadle BM, Johnson FM, Morrison WH, Phan J, Frank SJ, Kies MS, Sturgis EM. Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer. Cancer 122(11):1702-7, 2016. e-Pub 2016. PMID: 27019396.
Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H, Naing A, Bauer TM, Piha-Paul S, Johnson FM, Kurzrock R, Golden L, Hynes S, Lin J, Lin AB, Bendell J. Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. J Clin Oncol 34(15):1764-71, 2016. e-Pub 2016. PMID: 27044938.
Ferrarotto R, Goonatilake R, Yoo SY, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J, Byers LA, Johnson FM. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clin Cancer Res 22(7):1674-86, 2016. e-Pub 2016. PMID: 26597303.
Nien HH, Sturgis EM, Kies MS, El-Naggar AK, Morrison WH, Beadle BM, Johnson FM, Gunn GB, Fuller CD, Phan J, Gold KA, Frank SJ, Skinner H, Rosenthal DI, Garden AS. Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. Head Neck 38 Suppl 1:E1554-61, 2016. e-Pub 2016. PMID: 26595157.
Peng S, Sen B, Mazumdar T, Byers LA, Diao L, Wang J, Tong P, Giri U, Heymach JV, Kadara HN, Johnson FM. Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations. Oncotarget 7(1):565-79, 2016. e-Pub 2016. PMID: 26623721.
Tanaka N, Patel AA, Wang J, Frederick MJ, Kalu NN, Zhao M, Fitzgerald AL, Xie TX, Silver NL, Caulin C, Zhou G, Skinner HD, Johnson FM, Myers JN, Osman AA. Wee-1 kinase inhibition sensitizes high risk HPV+ HNSCC to apoptosis accompanied by downregulation of MCl-1 and XIAP antiapoptotic proteins. Clin Cancer Res 21(21):4831-44, 2015. e-Pub 2015. PMID: 26124202.
Mazumdar T, Sen B, Wang Y, Peng S, Nicholas C, Glisson BS, Myers JN, Johnson FM. Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers. Anticancer Drugs 26(8):835-42, 2015. e-Pub 2015. PMID: 26053277.
Tong P, Coombes KR, Johnson FM, Byers LA, Diao L, Liu DD, Lee JJ, Heymach JV, Wang J. drexplorer: A tool to explore dose-response relationships and drug-drug interactions. Bioinformatics 31(10):1692-4, 2015. e-Pub 2015. PMID: 25600946.
Recondo G, Busaidy N, Erasmus J, Williams MD, Johnson FM. Spindle epithelial tumor with thymus-like differentiation: A case report and comprehensive review of the literature and treatment options. Head Neck 37(5):746-54, 2015. e-Pub 2015. PMID: 24677409.
Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens AW, Simantov R, Poondru S, Gedrich R, Lippman SM, Kaye SB, Carden CP. Phase I Study of Intermittent Oral Dosing of the Insulin-Like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors. Clin Cancer Res 21(4):693-700, 2015. e-Pub 2015. PMID: 25208878.
Hao C, Wang L, Peng S, Cao M, Li H, Hu J, Huang X, Liu W, Zhang H, Wu S, Pataer A, Heymach JV, Eterovic AK, Zhang Q, Shaw KR, Chen K, Futreal A, Wang M, Hofstetter W, Mehran R, Rice D, Roth JA, Sepesi B, Swisher SG, Vaporciyan A, Walsh GL, Johnson FM, Fang B. Gene mutations in primary tumors and corresponding patientderived xenografts derived from non-small cell lung cancer. Cancer Lett 357(1):179-85, 2015. e-Pub 2015. PMID: 25444907.
Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao L, Fan YH, Stemke-Hale K, Heymach JV, Myers JN, Glisson BS, Johnson FM. A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma. Mol Cancer Ther 13(11):2738-50, 2014. e-Pub 2014. PMID: 25193510.
Gold KA, Lee JJ, Harun N, Tang X, Price J, Kawedia JD, Tran HT, Erasmus JJ, Blumenschein GR, William WN, Wistuba II, Johnson FM. A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer. Oncologist 19(10):1040-1, 2014. e-Pub 2014. PMID: 25170013.
Shin DH, Lee HJ, Min HY, Choi SP, Lee MS, Lee JW, Johnson FM, Mehta K, Lippman SM, Glisson BS, Lee HY. Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β3-Src Pathway. J Natl Cancer Inst 105(20):1558-70, 2013. e-Pub 2013. PMID: 24092920.
Sandulache VC, Ow TJ, Daram SP, Hamilton J, Skinner H, Bell D, Rosenthal DI, Beadle BM, Ang KK, Kies MS, Johnson FM, El-Naggar AK, Myers JN. Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival. Head Neck 35(10):1454-60, 2013. e-Pub 2013. PMID: 23018868.
Peng S, Creighton CJ, Zhang Y, Sen B, Mazumdar T, Myers JN, Lai SY, Woolfson A, Lorenzi MV, Bell D, Williams MD, Johnson FM. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers. J Transl Med 11(1):198, 2013. e-Pub 2013. PMID: 23981300.
Guo C, Shao R, Correa AM, Behrens C, Johnson FM, Raso MG, Prudkin L, Solis LM, Nunez MI, Fang B, Roth JA, Wistuba II, Swisher SG, Lin T, Pataer A. Prognostic Significance of Combinations of RNA-Dependent Protein Kinase and EphA2 Biomarkers for NSCLC. J Thorac Oncol 8(3):301-8, 2013. e-Pub 2013. PMID: 23370317.
Saintigny P, Peng S, Zhang L, Sen B, Wistuba II, Lippman SM, Girard L, Minna JD, Heymach JV, Johnson FM. Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion. Mol Cancer Ther 11(9):2021-2032, 2012. e-Pub 2012. PMID: 22807579.
Raju U, Riesterer O, Wang ZQ, Molkentine DP, Molkentine JM, Johnson FM, Glisson B, Milas L, Ang KK. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. Radiother Oncol 12:00361-1. e-Pub 2012. PMID: 23010482.
Sen B, Peng S, Tang X, Erickson HS, Galindo H, Mazumdar T, Stewart DJ, Wistuba I, Johnson FM. Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib. Sci Transl Med 4(136):136ra70, 2012. e-Pub 2012. PMID: 22649091.
Sen B, Peng S, Woods DM, Wistuba I, Bell D, El-Naggar AK, Lai SY, Johnson FM. STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. Clin Cancer Res 18(1):127-39, 2012. e-Pub 2012. PMID: 22090359.
Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 117(10):2112-9, 2011. e-Pub 2011. PMID: 21523723.
Sen B, Peng S, Saigal B, Williams MD, Johnson FM. Distinct interactions between c-Src and C-Met in mediating resistance to c-Src inhibition in head and neck Cancer. Clin Cancer Res 17(3):514-24, 2011. e-Pub 2011. PMID: 21106725.
Sen B, Johnson FM. Regulation of SRC family kinases in human cancers. J Signal Transduct 2011:865819, 2011. e-Pub 2011. PMID: 21776389.
Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ. Phase II Study of Dasatinib in Patients with Advanced Non-Small Cell Lung Cancer. J Clin Oncol 28(30):4609-4615, 2010. e-Pub 2010. PMID: 20855820.
Taoudi Benchekroun M, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Lang W, Fan YH, Huang J, Feng L, Lee JJ, Kim ES, Hong WK, Johnson FM, Grandis JR, Mao L. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) 3(7):800-9, 2010. e-Pub 2010. PMID: 20570883.
Haura EB, Camidge DR, Reckamp K, Chiappori A, Johnson F, Herbst R, Wong K, Carbone D. Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy. J Thorac Oncol 5(6):S207, 2010. e-Pub 2010. PMID: 20502275.
Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie JM, Wistuba II, Heymach JV. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene 29(18):2616-27, 2010. e-Pub 2010. PMID: 20154724.
William WN, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small celllung carcinoma. Cancer 116(10):2409-15, 2010. e-Pub 2010. PMID: 20225329.
Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, Blackwood-Chirchir A, Luo FR, Sy O, Kaul S, Chiappori AA. Phase I, Pharmacokinetic, and Drug Interaction Study of Dasatinib in Patients with Advanced Solid Tumors. Cancer 116(6):1582-91, 2010. e-Pub 2010. PMID: 20108303.
Brannan JM, Sen B, Saigal B, Prudkin L, Behrens C, Solis L, Dong W, Bekele BN, Wistuba I, Johnson FM. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila) 2(12):1039-49, 2009. e-Pub 2009. PMID: 19934338.
Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach JV, Johnson FM. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 15(22):6852-61, 2009. e-Pub 2009. PMID: 19861436.
Johnson FM, Glisson BS. Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?. Nat Rev Clin Oncol 6(10):562-3, 2009. e-Pub 2009. PMID: 19786998.
Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, Wistuba I, Johnson FM. Expression of the Receptor Tyrosine Kinase EphA2 Is Increased in Smokers and Predicts Poor Survival in Non-Small Cell Lung Cancer. Clin Cancer Res 15(13):4423-30, 2009. e-Pub 2009. PMID: 19531623.
Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G, Johnson FM, Green S, Gualberto A. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27(15):2516-22, 2009. e-Pub 2009. PMID: 19380445.
Sen B, Saigal B, Parikh N, Gallick G, Johnson FM. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res 69(5):1958-65, 2009. e-Pub 2009. PMID: 19223541.
Braiteh F, Kurzrock R, Johnson FM. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol 26(20):3460-2, 2008. e-Pub 2008. PMID: 18612164.
Saigal B, Glisson BS, Johnson FM. Dose-and Sequence-dependent Cyotoxicity of Erlotinib and Docetaxel in Head and Neck Squamous Cell Carcinoma. Anticancer Drugs 19(5):465-475, 2008. e-Pub 2008. PMID: 18418213.
Mandal M, Myers JN, Lippman SM, Johnson FM, Williams MD, Rayala S, Ohshiro K, Rosenthal DI, Weber RS, Gallick GE, El-Naggar AK. Epithelial to mesenchymal transition in head and neck squamous carcinoma: associationof Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 112(9):2088-100, 2008. e-Pub 2008. PMID: 18327819.
Yang Y, Wislez M, Fujimoto N, Prudkin L, Izzo JG, Uno F, Ji L, Hanna AE, Langley RR, Liu D, Johnson FM, Wistuba I, Kurie JM. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther 7(4):952-60, 2008. e-Pub 2008. PMID: 18413809.
Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 6(7):1962-72, 2007. e-Pub 2007. PMID: 17620427.
Johnson FM, Saigal B, Tran H, Donato NJ. Abrogation of signal transducer and activator of transcription 3 reactivation after Src Kinase Inhibition results in Synergistic Antitumor Effects. Clin Cancer Res 13(14):4233-4244, 2007. e-Pub 2007. PMID: 17634553.
Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, Ma L, Wistuba II, Johnson FM, Kurie JM. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 170(1):366-76, 2007. e-Pub 2007. PMID: 17200208.
Johnson FM, Krug LM, Tran HT, Shoaf S, Prieto VG, Tamboli P, Peeples B, Patel J, Glisson BS. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in small cell lung cancer cells. Cancer 106(2):366-74, 2006. e-Pub 2006. PMID: 16342249.
Johnson FM, Garden AS, Palmer JL, Shin DM, Morrison W, Papadimitrakopoulou V, Khuri F, Clayman G, Goepfert H, Ang KK, Hong WK, Glisson BS. A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 63(3):717-24, 2005. e-Pub 2005. PMID: 16199307.
Johnson FM, Saigal B, Donato NJ. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cell. J Cell Physiol 205(2):218-27, 2005. e-Pub 2005. PMID: 15887238.
Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11(19):6924-32, 2005. e-Pub 2005. PMID: 16203784.
Johnson FM, Yang P, Newman RA, Donato NJ. Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate. J Exp Ther Oncol 4(4):317-25, 2004. e-Pub 2004. PMID: 15844661.
Johnson FM, Garden A, Palmer JL, Kies M, Clayman G, Brumfield B, Khuri FR, Morrison W, Papadimitrakopoulou V, Diaz EM, Glisson BS. A Phase II study of Docetaxel and Carboplatin as Neoadjuvant Therapy for patients with advanced Nasopharyngeal Carcinoma. Cancer 100(5):991-8, 2004. e-Pub 2004. PMID: 14983495.
Johnson FM, Kurie JM, Peeples BO, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park) 17(7 Suppl 7):17-21, 2003. e-Pub 2003. PMID: 12886869.
Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I Study of Dose-Dense Alternating Therapy with Irinotecan/Cisplatin and Etoposide/Cisplatin for Patients with Small-Cell Lung Cancer. Clin Lung Cancer 5(1):40-5, 2003. e-Pub 2003. PMID: 14596703.
Johnson FM, Shur BD. The level of cell surface beta1,4-galactosyltransferase I influences the invasive potential of murine melanoma cells. J Cell Sci 12(16):2785-95, 1999. e-Pub 1999. PMID: 10413685.
Johnson FM, Garcia A. Sepsis with group B streptococci (Streptococcus agalactiae) secondary to urinary tract infection in an adult male. J Am Geriatr Soc 47(5):629-30, 1999. e-Pub 1999. PMID: 10323662.

Review Articles

Ghosh S, Shah PA, Johnson FM. Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma. Int J Mol Sci 23(14), 2022. e-Pub 2022. PMID: 35887235.
Massarelli E, Johnson FM, Erickson HS, Wistuba II, Papadimitrakopoulou V. Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer 80(3):235-241, 2013. e-Pub 2013. PMID: 23485129.
Rothschild SI, Gautschi O, Haura EB, Johnson FM. Src inhibitors in Lung Cancer: Current Status and Future Directions. Clin Lung Cancer 11(4):238-42, 2010. e-Pub 2010. PMID: 20630825.
Lai SY, Johnson FM. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches. Drug Resist Updat 13(3):67-78, 2010. e-Pub 2010. PMID: 20471303.
Johnson FM, Gallick GE. SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem 7(6):651-9, 2007. e-Pub 2007. PMID: 18045060.

Abstracts

Ghosh S, O’Hara MP, Mazumdar T, Yapindi L, Shen L, Wang J, Frederick MJ, Sastry JK, Johnson FM. Aurora-A inhibition sensitizes HPV-driven cancers to anti-CTLA-4 immunotherapy by modulating the tumor immune microenvironment. American Association for Cancer Research (AACR), 2025. e-Pub 2025.
Yapindi L, Ghosh S, Shen L, Wang J, Johnson FM. Exploiting Rb-deficiency: Dual inhibition of TRIP13 and Aurora A as a path to mitotic catastrophe. American Association for Cancer Research (AACR), 2025. e-Pub 2025.
Colevas AD, Chung CH, Adkins D, Rodriguez CP, Park JC, Gibson MK, Sukari A, Worden AP, Johnson FM, Saba NF, Burtness B, Julian R A, Bauman JE, Jotte RM, Seiwert TY, Dunn L, Chaney MF, Margossian S, Levisetti M, PaiSI. A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC). 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
Yapindi L, Ghosh S, Mazumdar T, Johnson FM. The combination of TRIP13 and Aurora kinase A inhibition caused cell cycle specific DNA damage and death in Rb-deficient cancers. American Association for Cancer Research (AACR) Special Conference in Cancer Research: DNA Damage Repair: From Basic Science To Future Clinical Application Washington, DC, 2024. e-Pub 2024.
Chung CH, Colevas AD, Adkins DR, Rodriguez CP, Park JC, Gibson MK, Sukari A, Worden FP, Johnson FM, Burtnes B, Julian RA, Saba NF, Jotte RM, Seiwert TY, Dunn LA, Haddad RY, Gabrail NY, Bauman JE, Chaney M, Agensky L, Goel A, Margossian SP, Quayle SN, Levisetti M, Pai SA. A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab in recurrent/metastatic HPV16+ head and neck cancer patients. Society for Immunotherapy of Cancer (SITC) Annual Meeting - San Diego, CA, 2023. e-Pub 2023.
Johnson FM, O'Hara MP, Reuben A, Lee JJ, Qing Y, Tran HT, Ghosh S, Yapindi L, Jiang P, Blumenschein G, Sastry J. Alisertib and pembrolizumab in Rb-deficient head and neck squamous cell carcinomas (HNSCC). AACR-NCI-EORTC Molecular Targets Meeting, 2023. e-Pub 2023.
Chung CH, Colevas ADD, Adkins D, Rodriguez CP, Park JC, Gibson MK, Burtness B, Johnson FM, Julian RA, Saba NF, Worden FP, Dunn L, Seiwert TY, Jotte RM, Bauman JE, Chaney MF, Margossian S, Levisetti M, Pai SI. A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer. ASCO Annual Meeting, 2023. e-Pub 2023.
Ghosh S, Mazumdar T, Yapindi L, Sinha P, Sastry J, Johnson FM. Novel combination of TRIP13 and Aurora kinase A inhibition demonstrated extensive DNA damage and immunogenic cell death in RB-deficient cancers. American Association for Cancer Research Annual Meeting (AACR) - Orlando, FL, 2023. e-Pub 2023.
Sinha P, Ghosh S, Johnson FM, Sastry JK. Preclinical evaluation of immunomodulatory effects of aurora kinase inhibition in HPV+ cancers. American Association for Cancer Research Annual Meeting (AACR) - Orlando, FL, 2023. e-Pub 2023.
Shah PA, Mazumdar T, Powell RT, Shen L, Wang J, Stephen CC, Frederick MJ, Johnson FM. Concurrent inactivation of PI3K and PLK1 is synergistic and overcomes acquired resistance to PI3K inhibitors in NOTCH1MUT HNSCC. American Association for Cancer Research Annual Meeting (AACR) - Orlando, FL, 2023. e-Pub 2023.
Chung CH, Colevas AD, Adkins DR, Park JC, Rodriguez CP, Gibson MK, Sukari A, Burtness BA, Johnson FM, Julian RA, Saba NF, Dunn LA, Seiwert TY, Worden FP, Muzaffar J, Haddad RY, Gabrail NY, Bauman JE, Chaney M, Agensky L, Goel A, Lynam R, Margossian SP, Moniz RJ, Quayle SN, Pienta K, Levisetti M, Pai SI. A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer. Society for Immunotherapy of Cancer (SITC) Annual Meeting - Boston, MA, 2022. e-Pub 2022.
Chung CH, Colevas AD, Adkins DR, Rodriguez CP, Park JC, Gibson MK, Sukari A, Worden FP, Johnson FM, Burtnes B, Julian RA, Saba NF, Jotte RM, Seiwert TY, Dunn LA, Haddad RY, Gabrail NY, Bauman JE, Chaney M, Agensky L, Goel A, Margossian SP, Quayle SN, Levisetti M, Pai SA. A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer. Society for Immunotherapy of Cancer (SITC) Annual Meeting - Boston, MA, 2022. e-Pub 2022.
Chung CH, Colevas AD, Adkins DR, Rodriguez CP, Park JC, Gibson MK, Sukari A, Worden FP, Johnson FM, Burtnes B, Julian RA, Saba NF, Jotte RM, Seiwert TY, Dunn LA, Haddad RY, Gabrail NY, Bauman JE, Chaney M, Agensky L, Goel A, Margossian SP, Quayle SN, Levisetti M, Pai SA. A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer. ASCO Annual Meeting, 2022. e-Pub 2022.
Gross ND, Ferrarotto R, Amit M, Nagarajan P, Yuan Y, Bell D, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Mott F, Esmaeli B, Diaz E, Gidley P, Goepfert R, Lewis CM, Wargo JA, Weber RS, Myers J. Long-term outcomes of a phase II trial of neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN). ASCO Annual Meeting, 2022. e-Pub 2022.
Shah P, Fernandez AM, Sambandam V, Zhao H, Mazumdar T, Shen L, Wang J, Johnson FM. Aurora kinase B expression shields HNSCC from PI3K inhibition-induced apoptosis through downstream mediators AKT and PDK1. American Association for Cancer Research (AACR) Annual Meeting - New Orleans, La, 2022. e-Pub 2022.
Chung CH, Colevas, AD, Adkins D, Gibson MK, Rodriguez CP, Sukari A, Bauman JE, Wirth LJ, Johnson FM, Saba NF, Burtness B, Dunn L, Seiwert TY, Worden FP, Muzaffar J, Margossian S, Moniz R, Quayle SN, Levisetti M, Pai SA. A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer. American Society of Clinical Oncology (ASCO) Annual Meeting - Chicago, IL, 2022. e-Pub 2022.
Ghosh S, Mazumdar T, Xu W, Powell RT, Stephan C, Shen L, Pickering CR, Wang J, Johnson FM. Rb deficient HPV+ HNSCC experienced enhanced sensitivity to aurora kinase inhibitors by altering the balance of MAD2 and TRIP13 levels. American Association for Cancer Research (AACR) Annual Meeting - New Orleans, La, 2022. e-Pub 2022.
Gudikote J, Cascone T, Poteete A, Sitthideatphaiboon P, Patel S, Yang Y, Zhang F, Li L, Shen L, Nilsson M, Jones P, Wang J, Bourdon JC, Johnson FM, Heymach JV. Targeting nonsense-mediated decay restores p53 function in HPV-associated head and neck cancers. American Association for Cancer Research (AACR) Annual Meeting - New Orleans, La, 2022. e-Pub 2022.
Neto FL, Sousa LG, Johnson FM, Lee JJ, Frank SJ, Moreno AC, Dahlstrom K, Ferrarotto R. Comparative assessment of the eighth and seventh AJCC staging edition prognostic performance of patients with p16 positive oropharynx cancer. ASCO Annual Meeting, 2021. e-Pub 2021.
Shah PA, Mazumdar T, Powell RT, Shen L, Wang J, Stephen CC, Frederick MJ, Johnson FM. Identification of pathways that enhance cell death in NOTCH1-mutant HNSCC. American Association for Cancer Research Annual Meeting, 2021. e-Pub 2021.
Barbon CE, Peterson CB, Fuller CD, Lai S, Moreno AC, Johnson FM, Hutcheson KA. Prospective Validation of the Use It or Lose It Paradigm: Secondary Analysis of Sub-Acute Dietary Outcomes by Eat and Exercise Status During Oropharyngeal Radiotherapy. 2021 Proceedings of the ASTRO 63rd Annual Meeting, 2021. e-Pub 2021.
Barbon C, Peterson C, Dirba D, Gunn G, Frank S, Ferrarotto R, Johnson FM, Hessel A, Goepfert R, Gross N, Hutcheson K. Comparison of Prospective, Longitudinal Swallowing Function After Primary Intensity-Modulated Proton Therapy (IMPT) or Transoral Robotic Surgery (TORS) for Oropharyngeal Squamous Cell Carcinoma. American Society for Radiation Oncology (ASTRO) Annual Meeting, 2020. e-Pub 2020.
Gunn GB, Ferrarotto R, Johnson FM, Bell D, Cardoso R, Johnson JM, Rubin ML, Yuan Y, Frank SJ, Fuller CD, Rosenthal DI, Kupferman ME, Goepfert R, Hessel AC, Hutcheson KA, Gross ND. Prospective, longitudinal digital activity monitoring before and after treatment of low-risk oropharyngeal squamous cell carcinoma: A feasibility study. ASCO Annual Meeting, 2020. e-Pub 2020.
Johnson FM, Lee JJ, Schmitz D, Streefkerk H, Rolli M, Janku F, Frederick M. Single-arm study of bimiralisib in head and neck squamous cell carcinoma (HNSCC) patients (pts) harboring NOTCH1 loss of function (LOF) mutations. ASCO Annual Meeting, 2020. e-Pub 2020.
Barbon CE, Yao CM, Warneke CL, Elgohari B, Goepfert RP, Hessel AC, Kupferman ME, Lai S, Fuller CD, Gunn GB, Garden AS, Chronowski GM, Johnson FM, Lewin JS, Gross ND, Hutcheson KA. Dysphagia After Primary Tors vs Non-surgical Therapies for Low-to-Intermediate Risk Tonsil Cancer: A Prospective Registry Analysis. Multidisciplinary Heand and Neck Cancers Symposium, 2020. e-Pub 2020.
Sambandam V, Mazumdar T, Shen L, Zhao H, Peng S, Wang J, Johnson FM. Aurora kinases mediate resistance to PI3K inhibition in head and neck squamous cell carcinoma. Multidisciplinary Head and Neck Cancers Symposium, 2020. e-Pub 2020.
Ferrarotto R, Bell D, Rubin ML, Lee JJ, Johnson JM, Goepfert R, Phan J, Elamin Y, Myers J, Hessel AC, Johnson FM, Gillison ML, Sikora AG, Glisson BS, Gross ND. Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results. ASCO Annual Meeting - Chicago, IL, 2019. e-Pub 2019.
Le X, Pickering CR, Rubin ML, Netto F, Kies MS, Johnson FM, Lu C, Blumenschein, Jr GR, Bell D, Ginsberg LE, Wilson KF, Lewis J, Feng L, Wang J, Lee J J, William WN, Myers J. Induction chemotherapy with and without erlotinib in patients with oral cavity squamous cell carcinomas (OCSCCs) amenable for surgical resection. ASCO Annual Meeting - Chicago, IL, 2019. e-Pub 2019.
Gleber-Netto FO, Gao M, Rao X, Vellano CP, Marszalek JR, Wang J, Johnson FM, Pickering CR. Variations in HPV function are associated with patient outcome and identify new candidate therapeutic approaches. American Association for Cancer Research Annual Meeting (AACR) - Atlanta, Ga, 2019. e-Pub 2019.
Sambandam V, Shen L, Peng S, Mazumdar T, Pickering C, Myers J, Wang J, Frederick M, Johnson FM. PDK1 drives susceptibility of NOTCH1 mutant head and neck squamous carcinoma to PI3K/mTOR pathway inhibition. American Association for Cancer Research Annual Meeting (AACR) - Atlanta, Ga, 2019. e-Pub 2019.
Sambandam V, Shen L, Tong P, Mazumdar T, Singh R, Pickering CR, Myers JN, Wang J, Frederick M, Johnson FM. PI3K/mTOR pathway inhibition induces Aurora B mediated cell death in NOTCH1 mutant head and neck squamous (HNSCC) cells. American Association for Cancer Research Annual Meeting (AACR) - Chicago, IL, 2018. e-Pub 2018.
Glebber-Netto FO, Rao X, Erikson K, Akagi K, Johnson FM, Wang J, Califano J, Gillison ML, Myers JN, Pickering CR. Risk stratifıcation and biomarker discovery in HPV-positive oropharynx squamous cell carcinoma determined by HPV and human gene expression profıle associations. American Association for Cancer Research Annual Meeting (AACR) - Chicago, IL, 2018. e-Pub 2018.
Singh S, Viswanath P, Peng S, Sambandam V, Shen L, Li L, Wang J, Fang B, Johnson FM. Noncanonical c-Met activation mediates de novo and acquired resistance to polo-like kinase 1 inhibitor-induced apoptosis in non-small cell lung cancer. American Association for Cancer Research Annual Meeting (AACR) - Chicago, IL, 2018. e-Pub 2018.
Mazumdar T, Kalu NN, Peng S, Tong P, Li S, Wang J, Myers JN, Pickering CR, Brunell D, Stephan CC, Johnson FM. Pharmacogenomic screen identifies KMT2D mutations as a biomarker of sensitivity to Aurora kinase inhibition in head and neck and cervical squamous cell carcinoma. American Association for Cancer Research Annual Meeting (AACR) - Chicago, IL, 2018. e-Pub 2018.
Sambandam V, Shen L, Ton P, Mazumdar T, Jong J, Pickering C, Myers JN, Wang J, Frederick M, Johnson FM. Metabolic dysregulation drives sensitivity after PI3K/mTOR inhibition in HNSCC. J Cancer Sci Ther 9(7), 2017. e-Pub 2017.
William WN, Feng L, Kies MS, Ahmed S, Blumenschein GR, Glisson BS, Massarelli E, Johnson FM, Lu C, Papadimitrakopoulou V, Gold KA, Theriault RL, Heymach J, Kim ES. Randomized, double-blind, placebo-controlled, phase II trial of first-line platinum/docetaxel with or without erlotinib (E) in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinomas (HNSCCs). American Society of Clinical Oncology (ASCO) Annual Meeting, 2017. e-Pub 2017.
Singh R, Shen L, Tong P, Wang J, Johnson FM. c-Met activation mediates resistance to polo-like kinase 1 inhibitor-induced apoptosis in non-small cell lung cancer. American Association for Cancer Research Annual Meeting (AACR) - Washington DC, 2017. e-Pub 2017.
Gay CM, Tong P, Cardnell RJ, Xiao S, Kalu NN, Banerjee U, Bara RO, Johnson FM, Heymach JV, Wang J, Byers LA. Differential sensitivity analysis for resistant malignancies (DISARM), a novel approach for drug screen analysis, identifıes common candidate drugs across platinum-resistant cancer types. American Association for Cancer Research Annual Meeting (AACR) - Washington DC, 2017. e-Pub 2017.
Zhang M, Ratnakar S, Peng S, Mazumdar T, Li S, Tong P, Pickering C, Myers JN, Wang J, Johnson FM. Mutations of the lim protein ajuba mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell cycle inhibitors. American Association for Cancer Research Annual Meeting (AACR) - Washington DC, 2017. e-Pub 2017.
Sambandam V, Shen L, Tong P, Mazumdar T, Pickering C, Myers JN, Wang J, Frederick M, Johnson FM. Identification of NOTCH1 inactivating mutation as a therapeutic vulnerability to PI3K/mTOR pathway inhibition in head and neck squamous cell carcinoma (HNSCC). American Association for Cancer Research Annual Meeting (AACR) - Washington DC, 2017. e-Pub 2017.
Sambandam V, Shen L, Ming Z, Saigal R, Tong P, Mazumdar T, Byers LA, Frederick M, Pickering C, Myers JN, Wang J, Johnson FM. NOTCH1 inactivating mutation mediates sensitivity to PI3K/mTOR inhibitors in Head and Neck Squamous Cell Carcinoma. American Association of Cancer Research (AACR), New Orleans, LA, 2016. e-Pub 2016.
Kalu NN, Mazumdar T, Shen L, Tong P, Wang J, Byers LA, Johnson FM. Cell-based, high throughput screen for small molecule inducers of cell death in HPV-associated head and neck cancers. American Association of Cancer Research (AACR), New Orleans, LA, 2016. e-Pub 2016.
Singh R, Wang Y, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Wang J, Heymach JV, Johnson FM. The combination of Polo-Like Kinase 1 inhibition and erlotinib overcomes T790M-mediated drug resistance in vitro and in vivo in non-small cell lung cancer. American Association of Cancer Research (AACR), New Orleans, LA, 2016. e-Pub 2016.
Zhang M, Peng S, Mazumdar T, Sambandam V, Li S, Tong P, Li L, Byers L, Pickering C, Frederick M, Myers JN, Wang J, Johnson FM. Identification of biomarkers that predict response of head and neck squamous cell carcinoma to mitotic inhibitors. American Association of Cancer Research (AACR), New Orleans, LA, 2016. e-Pub 2016.
Wang Y, Nilsson, M, Heymach J, Goonatilake R, Giri U, Peng S, Tong P, Wang J, Johnson FM. Synergistic Effect of Polo-Like Kinase 1 and Epidermal Growth Factor Receptor (EGFR) Inhibition in Non-Small Cell Lung Cancer Cell Lines with Acquired EGFR Inhibitor Resistance. TxSACT Conference:Recent Advances in the Development of Combinatorial Therapies for Cancer, 2015. e-Pub 2015.
Zhang M, Mazumdar T, Sambandam V, Peng S, Tong P, Shen L, Myers J, Wang J, Johnson FM. Identification of Mitotic Inhibitors as Effective Drugs in HNSCC and Potential of Biomarkers of Response. TxSACT Conference:Recent Advances in the Development of Combinatorial Therapies for Cancer, 2015. e-Pub 2015.
Wang L, Singh R, Giri U, Peng S, Heymach J, Tong P, Shen L, Zhang M, Wang J, Johnson FM. Determining the Mechanism of Antagonism between PLK1 Inhibitors and DNA-Damaging Agents. TxSACT Conference:Recent Advances in the Development of Combinatorial Therapies for Cancer, 2015. e-Pub 2015.
Sambandam V, Shen L, Zhang M, Saigal R, Tong P, Mazumdar T, Byers LA, Pickering C, Myers JN, Wang J, Johnson FM. Integrating “Multiple-Omics” Data with Targeted Drug Screen of PI3K/mTOR Pathway Inhibitors to Identify Novel Combination Therapies for Head and Neck Squamous Cell Carcinoma (HNSCC). TxSACT Conference:Recent Advances in the Development of Combinatorial Therapies for Cancer, 2015. e-Pub 2015.
Singh R, Giri U, Peng S, Heymach J, Tong P, Wang J, Johnson FM. Identifying Biomarkers of Response to NMS-P937, a Novel PLK1 Inhibitor in NSCLC. TxSACT Conference:Recent Advances in the Development of Combinatorial Therapies for Cancer, 2015. e-Pub 2015.
Kato S, Jardim DL, Johnson FM, Subbiah V, Piha-Paul S, Tsimberidou AM, Falchook GS, Karp D, Wheler J, Zinner RG, Janku F, Fu S, Dandu L, Browne E, Meric-Bernstam F, Hong DS. Phase I study of combination of crizotinib (C) and dasatinib (D) in patients (pts) with advanced cancer. American Society of Clinical Oncology - Illumination & Innovation, 2015. e-Pub 2015.
Zhang M, Mazumdar T, Peng S, Tong P, Sambandam V, Byers L, Myers J, Wang J, Johnson FM. The difference of drug sensitivity between HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines. American Association for Cancer Research Annual Meeting, Philadelphia, Pennsylvania, 2015. e-Pub 2015.
Kalu N, Mazumdar T, Fan YH, Giri U, Diao L, Ng PKS, Wang J, Myers J, Johnson FM, Byers LA. Characterization of HPV-positive head and neck cancer cell lines as preclinical models for targeted therapy. American Association for Cancer Research, Philadelphia, Pennsylvania, 2015. e-Pub 2015.
Sambandam V, Shen L, Ming Z, Saigal R, Byers LA, Pickering C, Myers JN, Wang J, Johnson FM. Integrative drug sensitivity analysis of PI3K /mTOR pathway inhibitors in Head and Neck Squamous cell carcinoma (HNSCC). American Association for Cancer Research (AACR) Annual Meeting, 2015. e-Pub 2015.
Quinlan-Davidson SR, Morrison WH, Myers JN, Gunn GB, Johnson FM, Beadle BM, Gillenwater AM, Phan J, Frank SJ, William Jr WN, Fuller CD, Gold KA, Rosenthal DI, Garden AS. Postoperative IMRT for Patients with Oral Cavity Carcinoma. ASTRO 56th Annual Meeting - Targeting Cancer:Technology & Biology, 2014. e-Pub 2014.
Johnson F, Sen, Banibrata, Muzumdar T, Peng S, Kadara H, Diao L, Byers L. Kinase-impaired BRAF mutations as predictors of resistance and sensitivity. AACR Precision Medicine Series: Drug Sensitivity and Resistance: Improving Cancer Therapy, 2014. e-Pub 2014.
Bauman JE, Duvvuri U, Gooding WE, Gross ND, Song J, Wendell GY, Johnson FM, Wang L, Jimeno A, Sen M, Kass JI, Johnson JT, Ferris RL, Kim S, Rath TJ, Hirsch FR, Mills GB, Pollock NI, Flaherty JT, Grandis JR. Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: A randomized, double-blind window study in operable head and neck squamous cell carcinoma (HNSCC). 2014 American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2014. e-Pub 2014.
Byers LA, Diao L, Shing HN PK, Heymach C, Fan Y, El-Naggar A, Wang J, Mills G, Johnson FM. Proteomic profiling of HPV-positive head and neck cancer identifies new candidates for targeted therapy. American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2014. e-Pub 2014.
Massarelli E, Haddad RI, Lee JJ, Garden AS, Blumenschein Jr GR, William WN, Tishler, RB, Glisson BS, Gold KA, Johnson FM, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V. Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma. American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2014, 2014. e-Pub 2014.
Sen B, Peng S, Mazumdar T, Byers LA, Kadara H, Johnson FM. The multi- targeted kinase inhibitor dasatinib induces DNA damage, Hippo pathway engagement and senescence in lung cancer cell lines that possess kinase-inactivating BRAF mutations. American Association for Cancer Research, 2014. e-Pub 2014.
Mazumdar T, Byers L, Ng P, Mills GB, Peng S, Diao L, Fan Y, Stemke-Hale K, Heymach JV, Myers JN, Glisson BS, Johnson FM. Evalution of Predictive biomarkers and resistance mechanisms of P13K pathway inhibition in head and neck cancers for efficient targeting therapy. American Association for Cancer Research, 2014. e-Pub 2014.
Sen B, Mazumdar, Peng S, Hale K, Glisson BS, Johnson FM. Paradoxical activation of the RAF-MEK-ERK pathway in response to nilotinib induces synthetic lethality with MEK inhibition in head and neck cancer cells. American Association for Cancer Research Annual Meeting, Washington, DC, 2013. e-Pub 2013.
Mazumdar T, Byers LA, Peng S, Diao L, Hale KS, Glisson BS, Johnson FM. Genetic determinants of sensitivity of resistance to P13K inhibitors in head and neck cancers for efficient targeted therapy. American Association for Cancer Research Annual Meeting, Washington, DC, 2013. e-Pub 2013.
Peng S, Creighton C, Zhang Y, Sen B, Mazumdar T, Myers J, Bell D, El-Nagger A, Williams MD, Johnson FM. Molecular and histologic characterization a patient-derived heterotransplant mouse model of head and neck squamous carcinoma. American Association for Cancer Research Annual Meeting, Washington, DC, 2013. e-Pub 2013.
Nicholas C, Nunez M, Harun N, Lee JJ, Myers J, Wistuba II, Sen B, El-Naggar AK, Lai S, Johnson FM, William WN. SOCS2 (suppressor of cytokine signaling protein 2) is a prognostic indicator of progression-free survival in head and neck squamous cell carcinoma (HNSCC) patients. American Association for Cancer Research Annual Meeting, Washington DC, 2013. e-Pub 2013.
Ferrarotto R, Yoo SY, Suryavanshi M, Wang J, Wistuba I, Glisson B, Geymach J, Johnson F. Identifying biomarkers of sensitivity to polo-like kinase (Plk) inhibitors in Non-Small Cell Lung Cancer (NSCLC). Targeted Therapies of the Treatment of Lung Cancer Meeting, IASLC, Santa Monica, CA, 2013. e-Pub 2013.
Ferrarotto R, Suryavanshi M, Young Yoo S, Wang J, Byers L, Glisson B S, Heymach J, Johnson FM. Identifying biomarkers of sensitivity to polo-like kinase inhibitors (Plki) in non small cell lung cancer (NSCLC). 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2013. e-Pub 2013.
Johnson FM, Tang XM, Tran HT, Mc Intyre C, Price J, Lee JJ, Harun N, Wistuba II, Gold KA. A phase I/II study combining dasatinib (D) and erlotinib (E) in non-small cell lung cancer. American Society of Clinical Oncology, Annual Meeting, Chicago, Illinois, 2013. e-Pub 2013.
Peng S, Sen B, Mazumdar, Myers J, Bell D, Williams M, EL-Naggar A, Johnson FM. Establishing a patient-derived heterotransplant mouse model of head and neck squamous carcinoma (HNSCC). American Association for Cancer Research Annual Meeting, Chicago, Illinois, 2012. e-Pub 2012.
Sen B, Peng, Tang X, Erickson H, Galindo H, Mazumdar T, Stewart DJ, Wistuba, Johnson FM. Inactivating BRAF mutations confer dasatinib sensitivity in lung cancer. American Association for Cancer Research Annual Meeting, Chicago, Illinois, 2012. e-Pub 2012.
Peng S, Saintigny P, Minna J, Zhang L, Lippman SM, Heymach J, Wistuba I, Sen B, Johnson FM. EphA4 is a novel tumor suppressor in lung adenocarcinoma. American Association for Cancer Research Annual Meeting, Orlando, FL, 2011. e-Pub 2011.
Sen B, Peng S, Saigal B, Williams M, Johnson FM. Differential interactions between c-Src and c-Met mediate resistance to c-Src inhibitors. American Association Annual Meeting, Orlando, FL, 2011. e-Pub 2011.
Johnson FM, Bekele Nebiyou B, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus J, Hwang L, Takebe N, Blumenschein G, Lippman S, Stewart D. Phase II Study of Dasatinib in Patients with Advanced Non–Small Cell Lung Cancer. American Society of Clinical Oncology, 2010. e-Pub 2010.
Sen B, Peng S, Johnson FM. JAK/STAT activation following Src inhibition is mediated by the loss of SOCS2 expression. American Association for Cancer Research, 2010. e-Pub 2010.
Byers AL, Sen B, Saigal B, Nanjundam, Mills G, Heymach J, Johnson FM. Reciprocal regulation of Src and STAT3 activation in non-small cell lung cancer. American Association for Cancer Research Annual Meeting, Denver CO, 2009. e-Pub 2009.
Saigal B, Johnson FM. Pathways mediating apoptosis and cell cycle arrest downstream of Src family kinases in aerodigestive tumors. American Association for Cancer Research Annual Meeting, 2008. e-Pub 2008.
Sen B, Saigal B, Johnson F. STAT3 knock down following Src kinase inhibition enhances apoptosis. American Association for Cancer Research Annual Meeting, San Diego, CA, 2008. e-Pub 2008.
Brannan JM, Ozburn NC, Prudkin ML, Dong W, Bekele BN, Wistuba II, Johnson FM. Knockdown of the tyrosine kinase EphA2 leads to decreased migration and colony size in non-small cell lung cancer (NSCLC) cell lines. American Association for Cancer Research Annual Meeting, 2008. e-Pub 2008.
Raju U, Johnson FM, Glisson BS, Riesterer O, Milas L, Ang KK. Mechanisms of enhanced radiosensitivity of human head and neck squamous cell carcinomas by dasatinib (BMS-354825, an inhibitor of Src kinases) include induction of apoptosis and inhibitionof DNA repair. American Association for Cancer Research Annual Meeting, San Diego, CA, 2008. e-Pub 2008.
Xu L, Nilsson MB, Hanrahan E, Cascone T, Yang Y, Du D, Prudkin L, Liu D, Engelman, J, Johnson F, Kurie J, Wistuba I, Heymach JV. Activated EGFR regulates invasiveness of Non-Cell Lung Cancer through HIF-1α mediated MET expression and is associated with increased Met levels in tumors from NSCLC patients. American Association for Cancer Research Annual Meeting, Los Angeles, CA, 2007. e-Pub 2007.
Tsao A, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba II, Johnson FM. Activated Src kinase is expressed in malignant pleural mesothelioma tumors; dasatinib inhibition leads to cytotoxicity, cell cycle inhibition, and prevention of invasion and migration. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, 2007. e-Pub 2007.
Raju U, Koto M, Johnson FM, Glisson B, Milas L, of head AKMD, carcinoma radioresistance NSC. Molecular determinants of head and neck squamous cell carcinoma radioresistance: A novel treatment strategy to improve radiotherapy outcome. American Association for Cancer Research Annual Meeting, Los Angles, CA, 2007. e-Pub 2007.
Kopetz S, Wu J, Donato N, Davies M, Parikh N, Gallick G, Johnson F. Synergistic activity of Src and EGFR inhibitors in colon cancer. American Association for Cancer Research Annual Meeting, Los Angeles, CA, 2007. e-Pub 2007.
Luo F, Wu C, McCann B, Mayfield S, Johnson F, Burris S, Chiappori A, Rosen L, Galbraith S, Blackwood-Chirchir A. Phase I Study (CA180021-Segment 1) to evaluate the effect of ketoconazole on the pharmacokinetics of dasatinib in patients with advanced solid tumors. American Association for Cancer Research Annual Meeting, Los Angeles, CA, 2007. e-Pub 2007.
Glisson B, Saigal B, Xu Y, Johnson F. Sequence-dependent cytoxicity of docetaxel and erlotinib in head and neck squamous cell carcinoma (HNSCC). American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, 2007. e-Pub 2007.
Brannan JM, Ozburn NC, Prudkin ML, Massarelli E, Bekele BN, Lopez-Berestein G, Sood AK, Wistuba II, Johnson FM. The presence of Ras mutations in NSCLC tissues correlates with increased expression of the receptor tyrosine kinase EphA2. American Association for Cancer Research Annual Meeting, Los Angeles, CA, 2007. e-Pub 2007.
Saigal B, Donato N, Tran HT, Johnson FM. Abrogation of STAT3 reactivagtion after Src kinase inhibition results in synergistic anti-tumor effects. American Association for Cancer Research Annual Meeting, Los Angeles, CA, 2007. e-Pub 2007.
Bakkannagari S, Saigal B, He D, Wistuba I, Hong WK, Johnson FM, Tsao AS. Inhibition of Src kinase in mesothelioma cell lines leads to cytotoxicity, inhibition of migration, and decreased invasion. American Association for Cancer Research Annual Meeting, Washington, D.C, 2006. e-Pub 2006.
Zhang J, Kalyankrishna S, Johnson F, Kurie JK. Src is constitutively activated in non-small cell lung cancer cells with mutant epidermal growth factor receptor and contributes to cell surviva. American Association for Cancer Research Annual Meeting, Washington, DC, 2006. e-Pub 2006.
Johnson FM, Saigal B, Talpaz M, Donato NJ. BMS-354825 multiple oncogenic tyrosine kinase inhibitor induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) cells. American Association for Cancer Research Annual Meeting, Anaheim, CA, 2005. e-Pub 2005.
Johnson FM, Tran HT, Johanson MJ, Prieto VG, Tamboli P, Peeples B, Glisson BS. Phase I trial of imatinib mesylate, cisplatin, and irinotecan in small cell lung cancer. International Chicago Symposium on Malignancies of the Chest and Head and Neck, Chicago, IL, 2004. e-Pub 2004.
Johnson FM, Garden A, Kies M, Clayman G, Brumfield B, Khuri F, Morrison W, Papadimitrakopoulou V, Diaz EM, Glisson BS. A phase II study of docetaxel and carboplatin as neoadjuvant therapy for patients with low T, High N stage nasophryngeal carcinoma. American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2003. e-Pub 2003.
Johnson FM, Yang P, Newman RA, Talpaz M, Donato NJ. The tyrosine kinase inhibitor ST1571 induces COX-2 expression and PGE2 accumulation in head and neck squamous cell carcinoma (HNSCC) via activation of MAPK. American Association for Cancer Research Annual Meeting, Washington, D.C, 2003. e-Pub 2003.
Johnson FM, Donato NJ, Talpaz M. Gleevec induces cell cycle arrest, apoptosis, and activation of MAPK in head and neck squamous carcinoma cells. American Association for Cancer Research Annual Meeting, San Francisco, California, 2002. e-Pub 2002.
Johnson FM, Kurie JM, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I trial of weekly etoposide, cisplatin, and irinotecan with G-CSF in patients with small cell lung cancer. American Society of Clinical Oncology Annual Meeting,Orlando, Flordia, 2002. e-Pub 2002.
Johnson FM, Shur BD. Cell Surface ß1,4-galactosyltransferase facilitates invasion and metastasis of K1735 murine melanoma cells. American Association for Cancer Research, Cancer: the interface between basic and applied research, Baltimore, MD, 1995. e-Pub 1995.
Johnson FM. Targeting TRIP13 in Cancer: Exploring Small Molecule Inhibitors in HPV related Models. The American Society for Microbiology's (ASM) conference (ABRCMS).
Amit M, Ferrarotto R, Nagarajan P, Li G, Yuan Y, Morrison W, Rosenthal D, Sousa L, Johnson F, Diaz E, Gidley P, Lewis C, Myers J, Gross N. Updated pathologic responses from a pilot phase II trial of neoadjuvant immunotherapy for stage II-IV resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN). ESMO 2025.

Book Chapters

Johnson FM, Epner DE. In: Empathy: Real Stories To Inspire And Enlighten Busy Clinicians, 2022.
Gibbons D, Pisters KM, and Johnson FM. Non-small Cell Lung Cancer. In: MD Anderson Manual of Clinical Oncology, 2011.
Sen B, Johnson FM. c-Src Family of Tyrosine Kinases. In: Encyclopedia of Signaling Molecules, 473-480, 2011.
Johnson FM, Gallick GE. Src Family Kinase Inhibitors in Cancer Therapy. In: In Serpins and Protein Kinase Inhibitors. Nova Science Publishers, Inc, 2009.
Johnson FM, Pisters KM. Non-small Cell Lung Cancer. In: MD Anderson Manual of Clinical Oncology. McGraw Hill, 2006.
Kim ES, Johnson FM, Hong WK, Khuri FR. Strategies for Cancer Chemoprevention. In: Cancer Chemoprevention. Human Press, 297-304, 2005.

Patents

Johnson FM. TREATMENT OF SQUAMOUS CELL CARCINOMA, 2025. Patent Number: 12,195,804.

Less

CV information above last modified March 13, 2026

Faye M. Johnson, M.D., Ph.D.

About Dr. Faye M. Johnson

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Review Articles

Other Articles

Abstracts

Book Chapters

Patents

Patient Reviews

Related Links

Johnson Laboratory

Thoracic/Head & Neck Medical Oncology department

Cancer Medicine division

Help #EndCancer

Faye M. Johnson, M.D., Ph.D.

About Dr. Faye M. Johnson

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Review Articles

Other Articles

Abstracts

Book Chapters

Patents

Patient Reviews

Request an Appointment

Related Links

Johnson Laboratory

Thoracic/Head & Neck Medical Oncology department

Cancer Medicine division

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson